Log in
Log in
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
Sign up
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     

AEON BIOPHARMA, INC.

(AEON)
End-of-day quote Nasdaq  - 
- USD   -.--%
2022AEON Biopharma, Inc. Reports Earnings Results for the Nine Months Ended September 30, 2022
CI
2022AEON Biopharma, Inc. Auditor Raises 'Going Concern' Doubt
CI
2022Aeon Biopharma Completes Enrollment in Phase 2 Trial of Abp-450 for Preventive Treatment of Episodic Migraine
CI
 SummaryQuotesNewsCompanyFunds 
Company
AEON Biopharma, Inc. is a clinical stage biopharmaceutical company. The Company is focused on developing botulinum toxin complex, ABP-450 (prabotulinumtoxinA) injection for debilitating medical conditions. The biologic ingredient in ABP-450 is Clostridium botulinum toxin, type A with a molecular weight of 900 kDa. Its initial development programs for ABP-450 are focused on migraine, cervical dystonia and... 
More about the company
All news about AEON BIOPHARMA, INC.
2022AEON Biopharma, Inc. Reports Earnings Results for the Nine Months Ended September 30, 2..
CI
2022AEON Biopharma, Inc. Auditor Raises 'Going Concern' Doubt
CI
2022Aeon Biopharma Completes Enrollment in Phase 2 Trial of Abp-450 for Preventive Treatmen..
CI
2022Overview : Proposed Merger Agreement with Priveterra Acquisition Corp. (Nasdaq: PMGM)
PU
2022AEON Biopharma, Inc. entered into a definitive busi..
CI
2022Aeon Biopharma Reports Positive Topline Results from Phase 2 Clinical Trial of ABP-450 ..
CI
2022AEON Biopharma, Inc. announced that it has received $30 million in funding
CI
2022AEON Biopharma, Inc. Announces Completion of Patient Enrollment in Phase 2 Clinical Stu..
CI
2021AEON Biopharma, Inc. has withdrawn its IPO in the amount of $80 million.
CI
2021AEON Biopharma, Inc. has filed an IPO in the amount of $75 million.
CI
2021ALPHAEON Corporation announced that it has received $30 million in funding from Daewoon..
CI
2020ALPHAEON Corporation announced that it expects to receive $25 million in funding .
CI
2019Certain Common Stock of Evolus, Inc. are subject to a Lock-Up Agreement Ending on 14-JA..
CI
2019Certain Stock Options of Evolus, Inc. are subject to a Lock-Up Agreement Ending on 14-J..
CI
2019Certain Restricted Stock Units of Evolus, Inc. are subject to a Lock-Up Agreement Endin..
CI
More news
News in other languages on AEON BIOPHARMA, INC.
2022AEON Biopharma, Inc. déclare ses résultats pour les neuf mois terminés le 30 septembre ..
2022AEON Biopharma, Inc. Le vérificateur soulève un doute quant à la continuité de l'exploi..
2022Aeon Biopharma termine le recrutement dans l'essai de phase 2 de l'Abp-450 pour le trai..
2022Aeon Biopharma annonce des résultats préliminaires positifs de l'essai clinique de phas..
2022AEON Biopharma, Inc. annonce la fin du recrutement des patients dans l'étude clinique d..
More news
Managers and Directors
Marc Forth President & Chief Executive Officer
Chris Carr Chief Financial Officer
Chad K. Oh Chief Medical Officer
Vikram Malik Director
Simone Blank Director
Sector and Competitors
1st jan.Capi. (M$)
AEON BIOPHARMA, INC.0.00%330
MODERNA, INC.7.58%72 745
LONZA GROUP AG17.24%42 787
IQVIA HOLDINGS INC.12.00%42 622
ALNYLAM PHARMACEUTICALS, INC.-2.55%28 465
SEAGEN INC.9.46%26 117